Study of Binimetinib With Encorafenib in Adults With Recurrent BRAF V600-Mutated HGG

计划入组 5 人 · 首次发布于 2019 年 6 月 4 日

A Study of RO5212054 (PLX3603) in Participants With BRAF V600-Mutated Advanced Solid Tumors

计划入组 45 人 · 首次发布于 2010 年 6 月 14 日

HDAC Inhibitor Vorinostat in Resistant BRAF V600 Mutated Advanced Melanoma

计划入组 33 人 · 首次发布于 2016 年 7 月 19 日

kinase inhibitor (CNS tumors)

Vemurafenib(Zelboraf)

C₂₃H₁₈ClF₂N₃O₃S · Rx

BRAF-V600E degrader

CNS Pharmaceuticals

United States

PRIMARY PHARMACEUTICALS, INC.

United States

CNS NETWORK INC

United States

FORE Biotherapeutics Advances Plixorafenib in BRAF-Driven Tumors, Eyes Potential FDA Submission

FORE Biotherapeutics Secures $38 Million in Series D-2 Financing to Advance Plixorafenib Clinical Trials

FORE Biotherapeutics Receives First-Ever Breakthrough Therapy Designation for High-Grade Glioma Targeted Therapy